scholarly journals The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies

2021 ◽  
Vol 11 ◽  
Author(s):  
Colette J. Shen ◽  
Stephanie A. Terezakis
Keyword(s):  
Soft Tissue ◽  
Molecular Diagnostics ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas ◽  
Critical Element ◽  
Precision Oncology ◽  
Tumor Characterization ◽  
Pediatric Cancers ◽  
Systemic Therapies

Ongoing rapid advances in molecular diagnostics, precision imaging, and development of targeted therapies have resulted in a constantly evolving landscape for treatment of pediatric cancers. Radiotherapy remains a critical element of the therapeutic toolbox, and its role in the era of precision medicine continues to adapt and undergo re-evaluation. Here, we review emerging strategies for combining radiotherapy with novel targeted systemic therapies (for example, for pediatric gliomas or soft tissue sarcomas), modifying use or intensity of radiotherapy when appropriate via molecular diagnostics that allow better characterization and individualization of each patient’s treatments (for example, de-intensification of radiotherapy in WNT subgroup medulloblastoma), as well as exploring more effective targeted systemic therapies that may allow omission or delay of radiotherapy. Many of these strategies are still under investigation but highlight the importance of continued pre-clinical and clinical studies evaluating the role of radiotherapy in this era of precision oncology.

Role of New Chemotherapy Agents in Soft Tissue Sarcoma

2005 ◽  
Vol 3 (2) ◽  
pp. 198-205
Author(s):  
Margaret von Mehren
Keyword(s):  
Soft Tissue ◽  
Single Agent ◽  
Growth Factor Receptor ◽  
Soft Tissue Sarcomas ◽  
Serine Threonine Kinase ◽  
Threonine Kinase ◽  
Cell Cycle Activation ◽  
Metastatic Gist ◽  
Chemotherapy Agents

Medical management of soft tissue sarcomas (STS) has been restricted by the limited availability of active drugs. A plethora of new oncologic agents are now available, many of which have specific therapeutic targets. Gemcitabine and docetaxel is a combination of drugs that have limited single-agent activity. Yondelis, a novel chemotherapeutic that binds DNA and functions partially by inhibiting transcription, is being tested alone and in combination with doxorubicin. Inhibitors of mTOR, a serine/threonine kinase that regulates cell cycle activation and cell growth, are also being tested. Growth factor receptor inhibitors are being evaluated in a variety of sarcomas that have been found to express the targets. In addition, a variety of agents are being assessed in gastrointestinal stromal tumors (GIST). Single agents and agents combined with imatinib are being tested in imatinib-refractory and in metastatic GIST. The increased use of targeted agents underscores the need for understanding sarcoma biology.

The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: Review of 30 cases

2009 ◽  
Vol 37 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Merdan Fayda ◽  
Gorkem Aksu ◽  
Fulya Yaman Agaoglu ◽  
Ahmet Karadeniz ◽  
Emin Darendeliler ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Head And Neck ◽  
Soft Tissue Sarcomas ◽  
Neck Region ◽  
Head And Neck Region

scholarly journals An update on adjuvant systemic therapies in melanoma

2019 ◽  
Vol 6 (3) ◽  
pp. MMT28 ◽  
Author(s):  
Evangeline Samuel ◽  
Maggie Moore ◽  
Mark Voskoboynik ◽  
Mark Shackleton ◽  
Andrew Haydon
Keyword(s):  
Adjuvant Therapy ◽  
Patient Outcomes ◽  
Targeted Therapies ◽  
Treatment Strategies ◽  
International Agency ◽  
Rising Incidence ◽  
Global Increase ◽  
Resected Stage ◽  
Systemic Therapies

There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.

scholarly journals Progress in the Systemic Treatment of Advanced Soft-Tissue Sarcomas

1998 ◽  
Vol 5 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Scott H. Okuno ◽  
John H. Edmonson
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Systemic Treatment ◽  
Soft Tissue Sarcomas ◽  
Multimodality Treatment ◽  
Clinical Situation ◽  
Controlled Clinical Trials ◽  
Systemic Treatments ◽  
Review Current ◽  
Systemic Therapies

Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current systemic treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the systemic treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.

The role of ifosfamide in paediatric soft tissue sarcomas

1986 ◽  
Vol 18 (S2) ◽  
pp. S23-S24 ◽  
Author(s):  
J. de Kraker ◽  
P. A. Voûte
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas

scholarly journals Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

2017 ◽  
Vol Volume 10 ◽  
pp. 1155-1164 ◽  
Author(s):  
Federica Recine ◽  
Alberto Bongiovanni ◽  
Nada Riva ◽  
Valentina Fausti ◽  
Alessandro De Vita ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas
Sign in / Sign up

Export Citation Format

Share Document